Modelling and optimizing combination therapeutic strategies for KRAS- and EGFR-mutant lung cancer

Non-small cell lung carcinoma (NSCLC) is well-known for its high incidence (about 80% of lung cancer) and genetic heterogeneity. Personalized driver mutations such as EGFR and KRAS have established targeted therapies with kinase inhibitors, whereas immune checkpoint inhibitors (ICIs) have revolution...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of bioinformatics and computational biology Jg. 23; H. 5; S. 2550017
Hauptverfasser:	Wu, Lanqi, Yu, Ruocheng, Yao, Minghui, Rahaman, Md Matiur, Fang, Zhaoyuan
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Singapore 01.10.2025
Schlagworte:	Animals Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Humans Immune Checkpoint Inhibitors - therapeutic use Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mice Mutation Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins p21(ras) - antagonists & inhibitors Proto-Oncogene Proteins p21(ras) - genetics combined therapy targeted therapy Lung cancer Boolean networks immunotherapy
ISSN:	1757-6334, 1757-6334
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!